Asia-Pacific Antibody Discovery Market Forecast to 2030 - Regional Analysis - by Antibody Type, Nature, Services, and End User

The Asia Pacific antibody discovery market was valued at US$ 6,58,965.05 million in 2022 and is expected to reach US$ 11,58,681.86 million by 2030; it is estimated to register a CAGR of 7.3% from 2022 to 2030.

Proliferation of Biotechnology Industry in Developing Regions Boosts Asia Pacific Antibody Discovery Market

The remarkable precision of antibodies in identifying antigens makes them invaluable tools for scientists and clinicians. In modern biotechnology, antibodies are required in numerous processes, from basic research to innovative medical evaluations. The development of therapeutic antibodies has opened new avenues in treating various diseases, demonstrating the transformative ability of these particles.

Antibodies are also crucial in antibody-based diagnostics as they provide accurate and reliable approaches to disease identification. Growing support from governments, rising public-private partnerships, continuously changing disease profiles, and increasing funding activities are widely enhancing the performance of biotechnology industries in the regions such as Asia Pacific.

As per the Organization for Economic Co-operation and Development (OECD), China was a frontrunner in terms of R&D expenditure as of 2019. Heavy investments encourage the adoption of advanced technologies in the healthcare sector. Governments of countries in regions such as Asia offer tax incentives, cheaper land, and direct investments for encouraging biotechnology companies to expand their capacities and strengthen their capabilities.

Thus, countries such as Taiwan, Malaysia, India, China, Singapore, and Japan are among the most advantageous destinations for the biotechnology industries. Furthermore, these Asian countries are more focused on using genomics, proteomics, and biomarker advancements for diagnostic and therapeutic applications. Therefore, the ongoing proliferation of biotechnology industries in developing regions is expected to create opportunities for the antibody discovery market in the coming years.

Asia Pacific Antibody Discovery Market Overview

The Asia Pacific antibody discovery market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China accounted for the largest share of the market in 2022, and India is expected to record a significant CAGR in the market during the forecast period. The biopharmaceutical industry in China is undergoing a tremendous shift, evolving from a generics-focused landscape to a thriving innovation hub. Additionally, progress in industrialization, and the application of novel drugs, high-end medical devices, and techniques contribute to the antibody discovery market growth in China.

China is experiencing an upsurge in the prevalence of cardiovascular disease and other chronic diseases. According to the Journal of Biomedical and Environmental Science, nearly 330 million people from the country suffered from cardiovascular diseases in 2021. Antibody products are crucial for the development of novel therapeutics against cardiovascular diseases. Therefore, a burgeoning prevalence of heart disease triggers the need for antibody discovery. With the help of research centers, antibody sequences can be researched, new and novel antibodies can be developed, and existing antibodies can be optimized.

According to the Scimago Institute Ranking, China had nearly 170 medical research centers as of 2022, followed by Japan (72), Australia (53), and India (17). Further, the growing number of market players focusing on countries in Asia Pacific for their geographic expansion and other growth strategies, the rising count of research centers, and a notable increase in government funding fuel the antibody discovery market growth in Asia Pacific.

Asia Pacific Antibody Discovery Market Revenue and Forecast to 2030 (US$ Billion)

Asia Pacific Antibody Discovery Market Segmentation

The Asia Pacific antibody discovery market is categorized into antibody type, nature, services, end user, and country.

Based on antibody type, the Asia Pacific antibody discovery market is segmented into monoclonal antibodies, polyclonal antibodies, and others. The monoclonal antibodies segment held the largest Asia Pacific antibody discovery market share in 2022.

In terms of nature, the Asia Pacific antibody discovery market is segmented into human and humanized, chimeric, and murine. The human and humanized segment held the largest Asia Pacific antibody discovery market share in 2022.

By services, the Asia Pacific antibody discovery market is divided into phage display, hybridoma, transgenic animal, single cell, and yeast display. The phage display segment held the largest Asia Pacific antibody discovery market share in 2022.

Based on end user, the Asia Pacific antibody discovery market is categorized into pharmaceutical and biotechnology companies, research laboratories, and others. The pharmaceutical and biotechnology companies segment held the largest Asia Pacific antibody discovery market share in 2022.

Based on country, the Asia Pacific antibody discovery market is categorized into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific antibody discovery market share in 2022.

Charles River Laboratories International Inc, BioDuro LLC, Sartorius AG, Aragen Life Sciences Ltd, Twist Bioscience Corp, and Biocytogen Pharmaceuticals Beijing Co Ltd. are some of the leading companies operating in the Asia Pacific antibody discovery market.